Mesoblast Limited (MESO) is in Healthcare, Biotechnology, based in Australia, listed on NasdaqGS. Market cap 1.79B USD. 52-week range 13.05 to 21.50 USD. Data as of 2026-10-09.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory ...